Andere talen Revive Therapeutics Ltd Toronto S.E.

Aandelen

RVV

CA7615161030

Vertraagde tijd Toronto S.E. Andere beurzen			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
- ^CAD	-.--%		+6,67%	-11,11%

18/04	Revive Therapeutics Ltd. Kondigt FDA Aanvaarding van Vergaderingsverzoek voor Long COVID Diagnostic Product aan	CI
02/04	Revive Therapeutics Ltd. Geeft een update over de klinische studie naar psilocybine voor methamphetaminegebruiksstoornis	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	29/02
Revive Therapeutics Explores the Use of Bucillamine for Long COVID	01/02
Revive Therapeutics Ltd. Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada	16/01
Revive Therapeutics Ltd. Successfully Completes Development of A Novel Lyophilized Formulation of Bucillamine	10/01
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of A Novel Lyophilized Formulation of Bucillamine	18/12
Revive Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2023	29/11
Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development	21/11
Revive Therapeutics Ltd.?s Newly-Formed Subsidiary, Revive Diagnostics Inc. Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize Novel Long COVID Rapid Test	06/11
Revive Therapeutics Ltd. Reports Earnings Results for the Full Year Ended June 30, 2023	27-10-23
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure	17-10-23
Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development	11-10-23
Revive Therapeutics Ltd. Announces Initiation of Novel Bucillamine Formulation Development	22-08-23
Revive Therapeutics Ltd. Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents	28-07-23
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19	06-07-23
Revive Therapeutics Ltd. Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19	30-05-23
Revive Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	30-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Revive Therapeutics Ltd Toronto S.E.

Aandelen

RVV

CA7615161030

Andere talen

Filters